Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. [electronic resource]
Producer: 20170808Description: 179-187 p. digitalISSN:- 1872-7980
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Caspase 3 -- metabolism
- Cell Cycle Proteins -- antagonists & inhibitors
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cyclin-Dependent Kinase Inhibitor p21 -- metabolism
- Dose-Response Relationship, Drug
- G2 Phase Cell Cycle Checkpoints -- drug effects
- Humans
- Ki-67 Antigen -- metabolism
- Melanoma -- drug therapy
- Mice, Nude
- Molecular Targeted Therapy
- Mutation
- Protein Kinase Inhibitors -- pharmacology
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Proto-Oncogene Proteins B-raf -- genetics
- Pteridines -- pharmacology
- S Phase Cell Cycle Checkpoints -- drug effects
- Signal Transduction -- drug effects
- Skin Neoplasms -- drug therapy
- Time Factors
- Tumor Burden -- drug effects
- Tumor Suppressor Protein p53 -- metabolism
- Xenograft Model Antitumor Assays
- Polo-Like Kinase 1
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.